Author
Samir M. Said
Other affiliations: Martin Luther University of Halle-Wittenberg
Bio: Samir M. Said is an academic researcher from Otto-von-Guericke University Magdeburg. The author has contributed to research in topics: Acute coronary syndrome & Atrial fibrillation. The author has an hindex of 12, co-authored 32 publications receiving 1794 citations. Previous affiliations of Samir M. Said include Martin Luther University of Halle-Wittenberg.
Papers
More filters
••
University of Zurich1, Hannover Medical School2, University of California, Davis3, Heidelberg University4, Ludwig Maximilian University of Munich5, Charité6, University of Kentucky7, University of Cologne8, Saarland University9, University of Duisburg-Essen10, University of Göttingen11, University of Ulm12, University of Hamburg13, Technische Universität München14, Otto-von-Guericke University Magdeburg15, John Radcliffe Hospital16, Winterthur Museum, Garden and Library17, University of Turku18, Gdańsk Medical University19, University of Warmia and Mazury in Olsztyn20, Medical University of Warsaw21, University of Cambridge22, University of Basel23, Catholic University of the Sacred Heart24, Innsbruck Medical University25, University of Greifswald26, Leiden University27, University of Glasgow28
TL;DR: Patients with takotsubo cardiomyopathy had a higher prevalence of neurologic or psychiatric disorders than did those with an acute coronary syndrome and physical triggers, acute neurologics or psychiatric diseases, high troponin levels, and a low ejection fraction on admission were independent predictors for in-hospital complications.
Abstract: BackgroundThe natural history, management, and outcome of takotsubo (stress) cardiomyopathy are incompletely understood. MethodsThe International Takotsubo Registry, a consortium of 26 centers in Europe and the United States, was established to investigate clinical features, prognostic predictors, and outcome of takotsubo cardiomyopathy. Patients were compared with age- and sex-matched patients who had an acute coronary syndrome. ResultsOf 1750 patients with takotsubo cardiomyopathy, 89.8% were women (mean age, 66.8 years). Emotional triggers were not as common as physical triggers (27.7% vs. 36.0%), and 28.5% of patients had no evident trigger. Among patients with takotsubo cardiomyopathy, as compared with an acute coronary syndrome, rates of neurologic or psychiatric disorders were higher (55.8% vs. 25.7%) and the mean left ventricular ejection fraction was markedly lower (40.7±11.2% vs. 51.5±12.3%) (P<0.001 for both comparisons). Rates of severe in-hospital complications including shock and death were ...
1,721 citations
••
University of Zurich1, University of California, San Diego2, University of Bremen3, University of Turin4, University Hospital Heidelberg5, University of Southern California6, Hannover Medical School7, Gdańsk Medical University8, Martin Luther University of Halle-Wittenberg9, Technische Universität München10, Leipzig University11, Charité12, HealthPartners13, University of Cologne14, University of Göttingen15, University of Kiel16, University of Ulm17, Otto-von-Guericke University Magdeburg18, John Radcliffe Hospital19, Winterthur Museum, Garden and Library20, Turku University Hospital21, Medical University of Warsaw22, University Hospital of Basel23, Catholic University of the Sacred Heart24, Greifswald University Hospital25, Heidelberg University26, University of Adelaide27, Charles University in Prague28, University of Florida29, Leiden University30, Mayo Clinic31, Imperial College London32
TL;DR: It is demonstrated that TTS can either be benign or a life-threating condition depending on the inciting stress factor, and a new classification based on triggers is proposed, which can serve as a clinical tool to predict short- and long-term outcomes of TTS.
192 citations
••
University of Zurich1, University of Turin2, University of Southern California3, University of California, San Diego4, University Hospital Heidelberg5, Hannover Medical School6, Gdańsk Medical University7, Martin Luther University of Halle-Wittenberg8, Technische Universität München9, Leipzig University10, Charité11, HealthPartners12, University of Cologne13, University of Göttingen14, University of Ulm15, Otto-von-Guericke University Magdeburg16, John Radcliffe Hospital17, Winterthur Museum, Garden and Library18, Turku University Hospital19, Medical University of Warsaw20, University Hospital of Basel21, Catholic University of the Sacred Heart22, Greifswald University Hospital23, Heidelberg University24, University of Adelaide25, Charles University in Prague26, University of Florida27, University of Bremen28, Leiden University29, Mayo Clinic30, Imperial College London31
TL;DR: Clinical and electrocardiographic parameters independently predicted mortality after cardiac arrest in takotsubo syndrome and cardiac arrest is relatively frequent in TTS and is associated with higher short- and long-term mortality.
Abstract: AIMS
We aimed to evaluate the frequency, clinical features, and prognostic implications of cardiac arrest (CA) in takotsubo syndrome (TTS).
METHODS AND RESULTS
We reviewed the records of patients with CA and known heart rhythm from the International Takotsubo Registry. The main outcomes were 60-day and 5-year mortality. In addition, predictors of mortality and predictors of CA during the acute TTS phase were assessed. Of 2098 patients, 103 patients with CA and known heart rhythm during CA were included. Compared with patients without CA, CA patients were more likely to be younger, male, and have apical TTS, atrial fibrillation (AF), neurologic comorbidities, physical triggers, and longer corrected QT-interval and lower left ventricular ejection fraction on admission. In all, 57.1% of patients with CA at admission had ventricular fibrillation/tachycardia, while 73.7% of patients with CA in the acute phase had asystole/pulseless electrical activity. Patients with CA showed higher 60-day (40.3% vs. 4.0%, P < 0.001) and 5-year mortality (68.9% vs. 16.7%, P < 0.001) than patients without CA. T-wave inversion and intracranial haemorrhage were independently associated with higher 60-day mortality after CA, whereas female gender was associated with lower 60-day mortality. In the acute phase, CA occurred less frequently in females and more frequently in patients with AF, ST-segment elevation, and higher C-reactive protein on admission.
CONCLUSIONS
Cardiac arrest is relatively frequent in TTS and is associated with higher short- and long-term mortality. Clinical and electrocardiographic parameters independently predicted mortality after CA.
65 citations
••
TL;DR: The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or compensated by administering higherImatinib doses, and there is no significant difference in the pharmacokinetic data obtained from patients with glioblastoma and CML.
Abstract: Background: Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II studies in recurrent glioblastoma multiforme (GBM). CYP3A4 enzyme-inducing antiepileptic drugs (EIAEDs) like carbamazepine, phenytoin, and oxcarbazepine - as well as non-EIAEDs like valproic acid, levetiracetam, and lamotrigine - are frequently used in patients with GBM. Since CYP3A4 is the major isozyme involved in the metabolism of imatinib, we investigated the influence of EIAEDs on imatinib pharmacokinetics (pk). Methods: GBM patients received 600 mg imatinib p.o./o.d. in combination with 1.0 g HU p.o./o.d..together with either EIAEDs, non-EIAEDs, or no antiepileptic drug (non-AEDs) comedication. Trough plasma levels of imatinib and its active main metabolite N-desmethyl-imatinib (CGP74588) were determined biweekly in these patients, total 543 samples being collected from 224 patients (up to 6 times / patient). All three groups were compared to each other and with historical pharmacokinetic data obtained from patients with chronic myeloid leukemia (CML). Results: Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%). Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs. Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%) , 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively. The corresponding mean level for CML patients was 300 ng/ml (CV 50%). Conclusion: Significant decreases of imatinib and CGP74588 trough levels were observed for patients receiving EIAEDs. The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or compensated by administering higher imatinib doses. In addition these data demonstrate that there is no significant difference in the pharmacokinetics of imatinib between patients with glioblastoma and CML.
65 citations
••
University of Zurich1, University of Turin2, University of Southern California3, Heidelberg University4, Hannover Medical School5, Gdańsk Medical University6, Martin Luther University of Halle-Wittenberg7, Technische Universität München8, Leipzig University9, Charité10, HealthPartners11, University of Cologne12, University of Göttingen13, University of Ulm14, John Radcliffe Hospital15, Winterthur Museum, Garden and Library16, Turku University Hospital17, Medical University of Warsaw18, University Hospital of Basel19, Catholic University of the Sacred Heart20, Greifswald University Hospital21, University of Adelaide22, Charles University in Prague23, University of Florida24, Mayo Clinic25, Leiden University26, Imperial College London27
TL;DR: The International Takotsubo Registry (www.takotubo-registry.com) is an observational, prospective, and retrospective registry established at the University Hospital Zurich in 2011, with the largest TTS database worldwide.
Abstract: The clinical course of takotsubo syndrome (TTS) can be complicated by several life-threatening conditions. In particular, cardiogenic shock (CS) represents one of the leading causes of mortality in the acute phase and occurs in a considerable number of patients with TTS, with an incidence of ≈10%. At present, no established guidelines are available to support specific treatment recommendations,and the conventional therapy for CS leads to uncertain results in TTS cases. The International Takotsubo Registry (www.takotsubo-registry.com) is an observational, prospective, and retrospective registry established at the University Hospital Zurich in 2011, with the largest TTS database worldwide. Patients were included in the registry between 2011 and 2017 based on modified Mayo Clinic Diagnostic criteria. Hospitalization data were recorded through standardized forms on admission or during revision of clinical charts; follow-up data were obtained from medical records, telephone follow-up, or clinical visits. The study population was categorized into 2 groups: patients with TTS with and without CS. The study protocol was reviewed by the respective local ethics committees or investigational review boards at each collaboration site. Where informed consent was required, formal written consent was obtained from patients.
61 citations
Cited by
More filters
••
TL;DR: This dissertation aims to provide a history of web exceptionalism from 1989 to 2002, a period chosen in order to explore its roots as well as specific cases up to and including the year in which descriptions of “Web 2.0” began to circulate.
Abstract: Kristian Thygesen∗ (Denmark)
Joseph S. Alpert∗ (USA)
Allan S. Jaffe (USA)
Bernard R. Chaitman (USA)
Jeroen J. Bax (The Netherlands)
David A. Morrow (USA)
Harvey D. White∗ (New Zealand)
Hans Mickley (Denmark)
Filippo Crea (Italy)
Frans Van de Werf (Belgium)
Chiara Bucciarelli-Ducci (
3,355 citations
••
[...]
TL;DR: From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory, and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia.
Abstract: From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory (D.C.F.), and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy (C.H.J.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. Address reprint requests to Dr. Fajgenbaum at davidfa@ pennmedicine . upenn . edu or to Dr. June at cjune@ upenn . edu.
1,517 citations
••
University of Zurich1, Johns Hopkins University2, Mayo Clinic3, St. Marianna University School of Medicine4, Catholic University of the Sacred Heart5, Katholieke Universiteit Leuven6, University of Ferrara7, University of Lübeck8, Yokohama City University9, University of Giessen10, Wakayama Medical University11, University of Padua12, Hiroshima University13, University of Florida14, Imperial College London15, University of Gothenburg16, Leiden University17, Karolinska Institutet18, University of Adelaide19, Tohoku University20
TL;DR: The clinical expert consensus document part I summarizes the current state of knowledge on clinical presentation and characteristics of TTS and agrees on controversies surrounding TTS such as nomenclature, different TTS types, role of coronary artery disease, and etiology.
Abstract: Takotsubo syndrome (TTS) is a poorly recognized heart disease that was initially regarded as a benign condition. Recently, it has been shown that TTS may be associated with severe clinical complications including death and that its prevalence is probably underestimated. Since current guidelines on TTS are lacking, it appears timely and important to provide an expert consensus statement on TTS. The clinical expert consensus document part I summarizes the current state of knowledge on clinical presentation and characteristics of TTS and agrees on controversies surrounding TTS such as nomenclature, different TTS types, role of coronary artery disease, and etiology. This consensus also proposes new diagnostic criteria based on current knowledge to improve diagnostic accuracy.
903 citations
••
National Institutes of Health1, University of Salerno2, Bosch3, St. George's University4, University of Sydney5, Royal North Shore Hospital6, St. Marianna University School of Medicine7, University of Zurich8, National and Kapodistrian University of Athens9, Paris Diderot University10, University of Gothenburg11
TL;DR: Novel structured approaches to diagnosis, risk stratification, and management are presented, with new algorithms to aid decision‐making by practising clinicians in the management of complex cases with ongoing symptoms after recovery, recurrent episodes, or spontaneous presentation.
Abstract: Takotsubo syndrome is an acute reversible heart failure syndrome that is increasingly recognized in modern cardiology practice. This Position Statement from the European Society of Cardiology Heart Failure Association provides a comprehensive review of the various clinical and pathophysiological facets of Takotsubo syndrome, including nomenclature, definition, and diagnosis, primary and secondary clinical subtypes, anatomical variants, triggers, epidemiology, pathophysiology, clinical presentation, complications, prognosis, clinical investigations, and treatment approaches. Novel structured approaches to diagnosis, risk stratification, and management are presented, with new algorithms to aid decision-making by practising clinicians. These also cover more complex areas (e.g. uncertain diagnosis and delayed presentation) and the management of complex cases with ongoing symptoms after recovery, recurrent episodes, or spontaneous presentation. The unmet needs and future directions for research in this syndrome are also discussed.
784 citations
•
20 Sep 2000
TL;DR: Thiazolidinediones(TDs)是一类新型的胰岛素抵抗治疗药物动物及临床实验证实TDs通过激活核受体过氧化物酶体增
Abstract: Thiazolidinediones(TDs)是一类新型的胰岛素抵抗治疗药物。动物及临床实验证实TDs通过激活核受体过氧化物酶体增殖物激活受体-γ(PPAR-γ)显著增加胰岛素敏感性,改善胰岛β-细胞功能,降低血糖和胰岛素水平,缓解高血压及脂代谢紊乱,对2型糖尿病大血管和微血管病变亦具有保护作用。临床使用耐受性好,低血糖发生率低。但其中的Troglitazone具有明显的肝脏毒性。
688 citations